JP2021533787A5 - - Google Patents
Info
- Publication number
- JP2021533787A5 JP2021533787A5 JP2021507927A JP2021507927A JP2021533787A5 JP 2021533787 A5 JP2021533787 A5 JP 2021533787A5 JP 2021507927 A JP2021507927 A JP 2021507927A JP 2021507927 A JP2021507927 A JP 2021507927A JP 2021533787 A5 JP2021533787 A5 JP 2021533787A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- genes listed
- endocrine therapy
- score
- pathway activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719545P | 2018-08-17 | 2018-08-17 | |
| US62/719,545 | 2018-08-17 | ||
| PCT/US2019/046814 WO2020037203A2 (en) | 2018-08-17 | 2019-08-16 | Diagnostic and therapeutic methods for the treatment of breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533787A JP2021533787A (ja) | 2021-12-09 |
| JP2021533787A5 true JP2021533787A5 (https=) | 2022-08-18 |
| JP7571006B2 JP7571006B2 (ja) | 2024-10-22 |
Family
ID=67809706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507927A Active JP7571006B2 (ja) | 2018-08-17 | 2019-08-16 | 乳がんの処置のための診断的および治療的方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11081236B2 (https=) |
| EP (1) | EP3837548A2 (https=) |
| JP (1) | JP7571006B2 (https=) |
| KR (1) | KR102754524B1 (https=) |
| CN (1) | CN113490850B (https=) |
| AU (1) | AU2019321588B2 (https=) |
| CA (1) | CA3109090A1 (https=) |
| IL (1) | IL280707B2 (https=) |
| MX (1) | MX2021001857A (https=) |
| TW (1) | TW202022124A (https=) |
| WO (1) | WO2020037203A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2909576T3 (es) * | 2016-10-11 | 2022-05-09 | Univ Duke | Tratamiento con lasofoxifeno del cáncer de mama ER+ |
| JP7571006B2 (ja) | 2018-08-17 | 2024-10-22 | ジェネンテック， インコーポレイテッド | 乳がんの処置のための診断的および治療的方法 |
| KR20220034129A (ko) | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체 길항제 요법 |
| AU2020399168A1 (en) * | 2019-12-09 | 2022-07-28 | Sanofi | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative |
| CA3169679A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| CN115551513B (zh) | 2020-05-12 | 2025-05-02 | 基因泰克公司 | 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌 |
| CN111893112A (zh) * | 2020-08-12 | 2020-11-06 | 上海尤里卡信息科技有限公司 | 胃癌肿瘤标志物及其应用 |
| CN114105977B (zh) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | 雌激素受体调节剂化合物及其用途 |
| EP4247977A2 (en) * | 2020-11-23 | 2023-09-27 | Sanofi | Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer |
| EP4267578A4 (en) | 2020-12-23 | 2024-11-20 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS |
| WO2022166983A1 (zh) * | 2021-02-08 | 2022-08-11 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| TWI808648B (zh) * | 2021-02-16 | 2023-07-11 | 美商建南德克公司 | 使用包含gdc-9545及gdc-0077之組合療法治療乳癌 |
| AU2022222660A1 (en) | 2021-02-16 | 2023-07-27 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib |
| JP2024506347A (ja) | 2021-02-16 | 2024-02-13 | ジェネンテック， インコーポレイテッド | Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置 |
| AU2022291768A1 (en) | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
| TW202317539A (zh) * | 2021-07-15 | 2023-05-01 | 大陸商四川海思科製藥有限公司 | 芳氨基衍生物雌激素受體調節劑及其用途 |
| US20240339201A1 (en) * | 2021-08-09 | 2024-10-10 | Korea University Research And Business Foundation | Breast cancer-related information providing method using magnetic resonance image and rna genetic information |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2023091550A1 (en) * | 2021-11-18 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| US20250263390A1 (en) * | 2022-04-15 | 2025-08-21 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| WO2024015506A1 (en) * | 2022-07-14 | 2024-01-18 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| JP2025533900A (ja) * | 2022-10-05 | 2025-10-09 | オレマ ファーマシューティカルズ， インコーポレイテッド | エストロゲン受容体媒介性障害を治療する方法 |
| WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| WO2025096907A1 (en) * | 2023-11-01 | 2025-05-08 | The Children's Medical Center Corporation | Methods and compositions for immunosuppressant resistant cellular therapies |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US6638727B1 (en) * | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| WO2002092854A2 (en) * | 2001-05-16 | 2002-11-21 | Novartis Ag | Genes expressed in breast cancer as prognostic and therapeutic targets |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| CA2539107A1 (en) | 2003-09-19 | 2005-03-31 | Arcturus Bioscience, Inc. | Predicting breast cancer treatment outcome |
| JP2010538609A (ja) * | 2007-09-06 | 2010-12-16 | バイオセラノスティクス，インコーポレイティド | 腫瘍グレード分類と癌の予後診断 |
| RS56042B1 (sr) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals Inc | Modulatori estrogenih receptora i njihove upotrebe |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| US9499538B2 (en) | 2012-03-20 | 2016-11-22 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US9169207B2 (en) * | 2012-03-27 | 2015-10-27 | Incuron, Llc | Curaxins for use in treating carcinogen-induced cancer |
| ES2696202T3 (es) | 2012-08-23 | 2019-01-14 | Univ Colorado Regents | Método para determinar el tratamiento de cáncer de mama |
| ES2774935T3 (es) | 2012-10-24 | 2020-07-23 | Univ Illinois | Composiciones y métodos para tratar trastornos médicos relacionados con estrógeno |
| EP2912033A4 (en) | 2012-10-24 | 2016-09-14 | Univ Illinois | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-MEDIATED ILLNESSES |
| EP2938745B1 (en) * | 2012-12-26 | 2020-10-07 | Koninklijke Philips N.V. | Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions |
| MX2015011132A (es) | 2013-03-14 | 2015-11-30 | Seragon Pharmaceuticals Inc | Moduladores policiclicos del receptor de estrogenos y sus usos. |
| BR112016005225B1 (pt) | 2013-09-11 | 2023-11-14 | Bio Theranostics, Inc | Métodos para avaliar câncer de mama em um indivíduo |
| ES3055185T3 (en) | 2014-03-28 | 2026-02-10 | Univ Duke | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator |
| BR112017007962A2 (pt) * | 2014-10-24 | 2018-01-23 | Koninklijke Philips Nv | método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit |
| TWI874834B (zh) | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| HK1258851A1 (zh) | 2015-11-09 | 2019-11-22 | 豪夫迈‧罗氏有限公司 | 四氢萘雌激素受体调节剂及其用途 |
| KR102479822B1 (ko) | 2016-02-05 | 2022-12-21 | 인벤티스바이오 엘엘씨 | 선택적 에스트로겐 수용체 분해제 및 이들의 용도 |
| EA034994B1 (ru) | 2016-02-15 | 2020-04-15 | Санофи | 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов |
| KR102111792B1 (ko) | 2016-03-25 | 2020-05-18 | 뤄신 바이오테크놀러지 (상하이) 컴퍼니 리미티드 | 에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물 |
| CN109843882A (zh) | 2016-06-16 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| EP3472162B1 (en) | 2016-06-16 | 2021-11-17 | F. Hoffmann-La Roche AG | Heteroaryl estrogen receptor modulators and uses thereof |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| EP3640251B1 (en) | 2016-10-24 | 2021-12-08 | Astrazeneca AB | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| CN110139863B (zh) | 2016-10-28 | 2022-02-18 | 罗欣健康科技发展(北京)有限公司 | 作为雌激素受体降解剂的吲哚并取代哌啶类化合物 |
| ES3039455T3 (en) | 2016-11-17 | 2025-10-21 | Sanofi Sa | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| JP7571006B2 (ja) | 2018-08-17 | 2024-10-22 | ジェネンテック， インコーポレイテッド | 乳がんの処置のための診断的および治療的方法 |
-
2019
- 2019-08-16 JP JP2021507927A patent/JP7571006B2/ja active Active
- 2019-08-16 CN CN201980067809.7A patent/CN113490850B/zh active Active
- 2019-08-16 CA CA3109090A patent/CA3109090A1/en active Pending
- 2019-08-16 IL IL280707A patent/IL280707B2/en unknown
- 2019-08-16 AU AU2019321588A patent/AU2019321588B2/en active Active
- 2019-08-16 TW TW108129347A patent/TW202022124A/zh unknown
- 2019-08-16 KR KR1020217007867A patent/KR102754524B1/ko active Active
- 2019-08-16 US US16/542,817 patent/US11081236B2/en active Active
- 2019-08-16 WO PCT/US2019/046814 patent/WO2020037203A2/en not_active Ceased
- 2019-08-16 MX MX2021001857A patent/MX2021001857A/es unknown
- 2019-08-16 EP EP19762044.6A patent/EP3837548A2/en active Pending
-
2021
- 2021-06-25 US US17/359,186 patent/US11676731B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533787A5 (https=) | ||
| Martín et al. | A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2–advanced breast cancer (BELLE-4) | |
| KR102871380B1 (ko) | 암을 치료하는 방법 | |
| Hojman et al. | Voluntary exercise prevents cisplatin-induced muscle wasting during chemotherapy in mice | |
| Pratz et al. | A prospective study of peritransplant sorafenib for patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic transplantation | |
| Du et al. | Comparative analysis of the immune responses in cancer cells irradiated with X-ray, proton and carbon-ion beams | |
| JP2021534129A5 (https=) | ||
| Carstensen et al. | Antiarrhythmic effects of combining dofetilide and ranolazine in a model of acutely induced atrial fibrillation in horses | |
| Mayer et al. | A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma | |
| KR20170018964A (ko) | 손-발 증후군 및 그와 관련된 증상의 치료방법 | |
| Varoquaux et al. | Endocrine tumors associated with the vagus nerve | |
| JP2020517739A (ja) | リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体２陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ | |
| Martin et al. | An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition | |
| Im et al. | Late DNA damage mediated by homologous recombination repair results in radiosensitization with gemcitabine | |
| US20250186393A1 (en) | Treatment of breast cancer with amcenestrant | |
| JP2010510495A5 (https=) | ||
| CN119173302A (zh) | 用于应用与个性化超分割立体定向适应性放射疗法相组合的肿瘤治疗电场的方法和仪器 | |
| Sameen et al. | A mathematical model for assessing KRAS mutation effect on monoclonal antibody treatment of colorectal cancer | |
| Brown et al. | Novel approaches in the treatment of thyroid cancer | |
| O’Brien | Emerging Data for Venetoclax in Chronic Lymphocytic Leukemia | |
| Li et al. | EP16. 03-043 Comprehensive Genomic Profiling of Tumor Mutational Burden-high in Chinese Lung Cancer Patients | |
| Kuehl et al. | MA17. 09 5-Azacytidine Inhaled Dry Powder Formulation Profoundly Improves Pharmacokinetics and Efficacy for Lung Cancer Therapy | |
| Duan | EP12. 01-29 Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib | |
| Fan et al. | EP12. 01-30 Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis | |
| Ganju et al. | ADJUNCTIVE GLP-1 RECEPTOR AGONISTS IN CROHN’S DISEASE: REDUCED STEROID DEPENDENCE AND HOSPITALIZATIONS IN A REAL-WORLD MULTI-NETWORK COHORT |